Feb 2019

Founded by seasoned pharmaceutical professional, Dr. Haribabu Bodepudi

Aug 2019

Experienced pharmaceutical professional Dr. Srihari Raju Kalidindi joins Viyash as Co-Founder

Sep 2019

Acquired controlling stake in Vindhya Pharma, focused on bulk intermediates and APIs

Nov 2019

Acquired controlling stake in Vandana Life Sciences, focused on bulk intermediates and APIs

Jul 2020

Commissioned API R&D facility to initiate Viyash's API development program across multiple therapeutic categories

Jan 2021

Acquired Mylan’s API and Formulations unit in Vizag

May 2021

Acquired Mylan’s US FDA approved API unit in Mumbai

Jun 2021

Acquired 100% ownership in Vindhya Pharma and Vandana Life Sciences

Jun 2021

Investment by Carlyle, one of the largest global PE fund

Jul 2021

Acquired Symed Labs, leading manufacturer of niche APIs

Nov 2021

Acquired majority stake in Appco Pharma LLC, US based generic formulations company

Nov 2021

Acquired 100% stake in Appcure Labs Private Limited, Hyderabad based generic drug development company


Viyash, true to its name, literally represents honesty and leadership in every sense.

We are an integrated pharmaceutical company with a strong portfolio of niche formulations, APIs and advanced intermediates Viyash and its subsidiaries operate 10 API / Intermediate facilities with a combined capacity ~2000 KL and diversified capabilities in every aspect - small / large volume, potent / non-potent, regulated / semi-regulated markets.

In addition, we also operate one formulation manufacturing facility in New Jersey, USA with a capacity of ~ 1.2 Bn units.

Leading from the front and staying honest about our origin mission, the two qualities associated with the Vedic interpretation of “Viyash”, are the propellers of success for any pharmaceutical initiative.We work professionally every day with a single-minded intent to build trust and honest relationships with our community and with our customers.

Our robust API and Formulations R&D infrastructure with a combined strength of over 200 scientists offers expertise across several technologies and complex reactions. Top that with a diversified mix of portfolio across multiple therapy areas such as ARV, CV, CNS, Analgesics, Antibiotics, Antihistamines, Diabetes, GI, Anticoagulants, Oncology etc., and you get the perfect Viyash potion.

Being young and agile while being bolstered by the heritage and the plethora of experiences the Viyash family brings with it, sets us well above the industry benchmarks. What we lack in age, we more than make up with our commitment towards our mission; High Quality and Cost efficiency